Symptomatic Cryptococcal Meningitis with Negative Serum and Cerebrospinal Fluid Cryptococcal Antigen Tests.

India ink amphotericin B cryptococcal antigen test cryptococcal meningitis fluconazole flucytosine

Journal

HIV/AIDS (Auckland, N.Z.)
ISSN: 1179-1373
Titre abrégé: HIV AIDS (Auckl)
Pays: New Zealand
ID NLM: 101515943

Informations de publication

Date de publication:
2021
Historique:
received: 06 07 2021
accepted: 26 08 2021
entrez: 13 9 2021
pubmed: 14 9 2021
medline: 14 9 2021
Statut: epublish

Résumé

Cryptococcal meningitis is a leading cause of mortality in advanced HIV disease. A positive cerebrospinal fluid cryptococcal antigen (CrAg) test defines cryptococcal meningitis. Herein, we present a patient with serum and cerebrospinal fluid CrAg negative cryptococcal meningitis, despite a positive cerebrospinal fluid India ink examination and quantitative culture. A 56-year-old HIV-positive Ugandan woman, with an undetectable HIV RNA viral load and CD4+ T-cell count of 766 cells per microlitre presented with signs and symptoms consistent with cryptococcal meningitis. Her serum and cerebrospinal fluid CrAg tests were negative despite having a positive cerebrospinal fluid India ink and quantitative culture. On day 1, she was commenced on intravenous amphotericin B deoxycholate (1mg/kg) for 3 days (considering 10 CFU growth of This report alerts clinicians managing patients with HIV-associated cryptococcal meningitis to four uncommon clinical scenarios; first, the possibility of negative serum and cerebrospinal fluid CrAg lateral flow assay results in the context of low cerebrospinal fluid fungal burden in a symptomatic patient. Second, possible occurrence of cryptococcal meningitis in a patient with high CD4 T-cell lymphocyte counts. Third, an early seroconversion of cryptococcal antigenaemia following effective fluconazole therapy. Fourth, an early symptomatic relapse of cryptococcal meningitis albeit negative serum CrAg.

Sections du résumé

BACKGROUND BACKGROUND
Cryptococcal meningitis is a leading cause of mortality in advanced HIV disease. A positive cerebrospinal fluid cryptococcal antigen (CrAg) test defines cryptococcal meningitis. Herein, we present a patient with serum and cerebrospinal fluid CrAg negative cryptococcal meningitis, despite a positive cerebrospinal fluid India ink examination and quantitative culture.
CASE DETAILS METHODS
A 56-year-old HIV-positive Ugandan woman, with an undetectable HIV RNA viral load and CD4+ T-cell count of 766 cells per microlitre presented with signs and symptoms consistent with cryptococcal meningitis. Her serum and cerebrospinal fluid CrAg tests were negative despite having a positive cerebrospinal fluid India ink and quantitative culture. On day 1, she was commenced on intravenous amphotericin B deoxycholate (1mg/kg) for 3 days (considering 10 CFU growth of
CONCLUSION CONCLUSIONS
This report alerts clinicians managing patients with HIV-associated cryptococcal meningitis to four uncommon clinical scenarios; first, the possibility of negative serum and cerebrospinal fluid CrAg lateral flow assay results in the context of low cerebrospinal fluid fungal burden in a symptomatic patient. Second, possible occurrence of cryptococcal meningitis in a patient with high CD4 T-cell lymphocyte counts. Third, an early seroconversion of cryptococcal antigenaemia following effective fluconazole therapy. Fourth, an early symptomatic relapse of cryptococcal meningitis albeit negative serum CrAg.

Identifiants

pubmed: 34512034
doi: 10.2147/HIV.S328084
pii: 328084
pmc: PMC8420644
doi:

Types de publication

Case Reports

Langues

eng

Pagination

861-865

Informations de copyright

© 2021 Nanfuka et al.

Déclaration de conflit d'intérêts

The authors report no conflicts of interest in this work.

Références

J Infect Dis. 2019 Feb 23;219(6):877-883
pubmed: 30325463
AIDS. 2002 May 3;16(7):1031-8
pubmed: 11953469
Eur J Clin Microbiol Infect Dis. 2019 Sep;38(9):1581-1584
pubmed: 31175479
mBio. 2017 Dec 12;8(6):
pubmed: 29233901
J Fungi (Basel). 2017 Dec 02;3(4):
pubmed: 29371581
Lancet Infect Dis. 2017 Aug;17(8):873-881
pubmed: 28483415
Clin Infect Dis. 2011 Nov;53(10):1019-23
pubmed: 21940419
Clin Infect Dis. 2021 Apr 8;72(7):1268-1278
pubmed: 32829406
Cureus. 2019 May 14;11(5):e4654
pubmed: 31316875
Lancet. 2015 May 30;385(9983):2128-9
pubmed: 25765697
Clin Infect Dis. 2010 Feb 1;50(3):291-322
pubmed: 20047480
Expert Opin Med Diagn. 2012 May;6(3):245-51
pubmed: 23480688
Emerg Infect Dis. 2014 Jan;20(1):45-53
pubmed: 24378231

Auteurs

Vivien Nanfuka (V)

Infectious Diseases Unit, Kiruddu National Referral Hospital, Kampala, Uganda.

Mkhoi L Mkhoi (ML)

Infectious Diseases Institute, College of Health Sciences, Makerere University, Kampala, Uganda.
Mark Wainberg Fellowship Programme, Infectious Diseases Institute, College of Health Sciences, Makerere University, Kampala, Uganda.
Department of Microbiology and Parasitology, College of Health Sciences, University of Dodoma, Dodoma, Tanzania.

Jane Gakuru (J)

Infectious Diseases Institute, College of Health Sciences, Makerere University, Kampala, Uganda.

Richard Kwizera (R)

Infectious Diseases Institute, College of Health Sciences, Makerere University, Kampala, Uganda.

Joseph Baruch Baluku (JB)

Division of Pulmonology, Kiruddu National Referral Hospital, Kampala, Uganda.

Felix Bongomin (F)

Department of Medicine, School of Medicine, College of Health Sciences, Makerere University, Kampala, Uganda.
Department of Medical Microbiology, Faculty of Medicine, Gulu University, Gulu, Uganda.

David B Meya (DB)

Infectious Diseases Unit, Kiruddu National Referral Hospital, Kampala, Uganda.
Infectious Diseases Institute, College of Health Sciences, Makerere University, Kampala, Uganda.
Department of Medicine, School of Medicine, College of Health Sciences, Makerere University, Kampala, Uganda.

Classifications MeSH